The European Medicines Agency met with European Union payers to discuss opportunities for collaboration.
In recent decades, delays in negotiating pricing and reimbursements have often come down to drugmakers’ focus on safety and quality testing — at the expense of completing cost-effectiveness research in a timely manner. Many companies conduct this work after receiving a marketing authorization, according to the EMA.
Timely, comprehensive data could make decision-making more efficient and get products to market faster, the agency said.
Follow-up meetings are being considered to explore similar opportunities to speed up access to products.